RITU TALWAR: Open Payments
NPI 1518124932 · NORTH CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$888 in 43 payments from 11 companies in 2025. Trend: 2023 $855 · 2024 $753 · 2025 $888
Food & beverage: $888
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $353 |
| Neurocrine BioSciences, Inc. | 4 | $95 |
| Otsuka America Pharmaceutical, Inc. | 3 | $89 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $85 |
| Alkermes, Inc. | 3 | $75 |
| Supernus Pharmaceuticals, Inc. | 3 | $60 |
| Lundbeck LLC | 2 | $46 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| Janssen Pharmaceuticals, Inc | 1 | $22 |
Products named: VRAYLAR, INGREZZA, CAPLYTA, REXULTI, ARISTADA, Qelbree, ABILIFY MAINTENA, Auvelity.
Industry payments across IL — which companies pay providers there.
